Literature DB >> 25377469

Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.

Caglar Cekic1, Yuan-Ji Day2, Duygu Sag3, Joel Linden4.   

Abstract

High concentrations of adenosine in tumor microenvironments inhibit antitumor cytotoxic lymphocyte responses. Although T cells express inhibitory adenosine A2A receptors (A2AR) that suppress their activation and inhibit immune killing of tumors, a role for myeloid cell A2ARs in suppressing the immune response to tumors has yet to be investigated. In this study, we show that the growth of transplanted syngeneic B16F10 melanoma or Lewis lung carcinoma cells is slowed in Adora2a(f/f)-LysMCre(+/-) mice, which selectively lack myeloid A2ARs. Reduced melanoma growth is associated with significant increases in MHCII and IL12 expression in tumor-associated macrophages and with >90% reductions in IL10 expression in tumor-associated macrophages, dendritic cells (DC), and Ly6C(+) or Ly6G(+) myeloid-derived suppressor cells (MDSC). Myeloid deletion of A2ARs significantly increases CD44 expression on tumor-associated T cells and natural killer (NK) cells. Depletion of CD8(+) T cells or NK cells in tumor-bearing mice indicates that both cell types initially contribute to slowing melanoma growth in mice lacking myeloid A2A receptors, but tumor suppression mediated by CD8(+) T cells is more persistent. Myeloid-selective A2AR deletion significantly reduces lung metastasis of melanomas that express luciferase (for in vivo tracking) and ovalbumin (as a model antigen). Reduced metastasis is associated with increased numbers and activation of NK cells and antigen-specific CD8(+) T cells in lung infiltrates. Overall, the findings indicate that myeloid cell A2ARs have direct myelosuppressive effects that indirectly contribute to the suppression of T cells and NK cells in primary and metastatic tumor microenvironments. The results indicate that tumor-associated myeloid cells, including macrophages, DCs, and MDSCs all express immunosuppressive A2ARs that are potential targets of adenosine receptor blockers to enhance immune killing of tumors. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25377469      PMCID: PMC4459782          DOI: 10.1158/0008-5472.CAN-13-3583

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

Review 1.  Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.

Authors:  Subhra K Biswas; Alberto Mantovani
Journal:  Nat Immunol       Date:  2010-09-20       Impact factor: 25.606

2.  Adenosine, inflammation pathways and therapeutic challenges.

Authors:  Balázs Csóka; György Haskó
Journal:  Joint Bone Spine       Date:  2011-01       Impact factor: 4.929

3.  Enhanced CD8 T cell cross-presentation by macrophages with targeted disruption of STAT3.

Authors:  Jason Brayer; Fengdong Cheng; Hongwei Wang; Pedro Horna; Ildefonso Vicente-Suarez; Javier Pinilla-Ibarz; Eduardo M Sotomayor
Journal:  Immunol Lett       Date:  2010-03-25       Impact factor: 3.685

4.  Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production.

Authors:  Aled Clayton; Saly Al-Taei; Jason Webber; Malcolm D Mason; Zsuzsanna Tabi
Journal:  J Immunol       Date:  2011-06-15       Impact factor: 5.422

5.  Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes.

Authors:  Kiavash Movahedi; Damya Laoui; Conny Gysemans; Martijn Baeten; Geert Stangé; Jan Van den Bossche; Matthias Mack; Daniel Pipeleers; Peter In't Veld; Patrick De Baetselier; Jo A Van Ginderachter
Journal:  Cancer Res       Date:  2010-06-22       Impact factor: 12.701

6.  CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression.

Authors:  Dachuan Jin; Jie Fan; Long Wang; Linda F Thompson; Aijie Liu; Benjamin J Daniel; Tahiro Shin; Tyler J Curiel; Bin Zhang
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

7.  MyD88-dependent SHIP1 regulates proinflammatory signaling pathways in dendritic cells after monophosphoryl lipid A stimulation of TLR4.

Authors:  Caglar Cekic; Carolyn R Casella; Duygu Sag; Frann Antignano; Joseph Kolb; Jill Suttles; Michael R Hughes; Gerald Krystal; Thomas C Mitchell
Journal:  J Immunol       Date:  2011-02-21       Impact factor: 5.422

Review 8.  Extracellular adenosine triphosphate and adenosine in cancer.

Authors:  J Stagg; M J Smyth
Journal:  Oncogene       Date:  2010-07-26       Impact factor: 9.867

9.  HIF-dependent induction of adenosine receptor A2b skews human dendritic cells to a Th2-stimulating phenotype under hypoxia.

Authors:  Meixiang Yang; Chunhong Ma; Shuxun Liu; Qianqian Shao; Wenjuan Gao; Bingfeng Song; Jintang Sun; Qi Xie; Yun Zhang; Alei Feng; Yanguo Liu; Weixu Hu; Xun Qu
Journal:  Immunol Cell Biol       Date:  2009-10-20       Impact factor: 5.126

Review 10.  Adenosine receptors: therapeutic aspects for inflammatory and immune diseases.

Authors:  György Haskó; Joel Linden; Bruce Cronstein; Pál Pacher
Journal:  Nat Rev Drug Discov       Date:  2008-09       Impact factor: 84.694

View more
  100 in total

Review 1.  Antibody-based immunotherapy of solid cancers: progress and possibilities.

Authors:  Christopher F Nicodemus
Journal:  Immunotherapy       Date:  2015-08-28       Impact factor: 4.196

2.  Intratumoral natural killer cells show reduced effector and cytolytic properties and control the differentiation of effector Th1 cells.

Authors:  Sourav Paul; Neeraja Kulkarni; Girdhari Lal
Journal:  Oncoimmunology       Date:  2016-09-20       Impact factor: 8.110

3.  A2A Adenosine Receptor Gene Deletion or Synthetic A2A Antagonist Liberate Tumor-Reactive CD8+ T Cells from Tumor-Induced Immunosuppression.

Authors:  Jorgen Kjaergaard; Stephen Hatfield; Graham Jones; Akio Ohta; Michail Sitkovsky
Journal:  J Immunol       Date:  2018-05-25       Impact factor: 5.422

Review 4.  Adenosinergic signaling as a target for natural killer cell immunotherapy.

Authors:  Jiao Wang; Sandro Matosevic
Journal:  J Mol Med (Berl)       Date:  2018-08-01       Impact factor: 4.599

5.  Anti-CD73 in cancer immunotherapy: awakening new opportunities.

Authors:  Luca Antonioli; Gennady G Yegutkin; Pál Pacher; Corrado Blandizzi; György Haskó
Journal:  Trends Cancer       Date:  2016-02-01

6.  Phenotypic and functional characteristics of CD39high human regulatory B cells (Breg).

Authors:  F Figueiró; L Muller; S Funk; E K Jackson; A M O Battastini; T L Whiteside
Journal:  Oncoimmunology       Date:  2016-02-26       Impact factor: 8.110

Review 7.  A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer.

Authors:  Stephen M Hatfield; Michail Sitkovsky
Journal:  Curr Opin Pharmacol       Date:  2016-07-17       Impact factor: 5.547

Review 8.  Purinergic regulation of the immune system.

Authors:  Caglar Cekic; Joel Linden
Journal:  Nat Rev Immunol       Date:  2016-03       Impact factor: 53.106

9.  The ecto-ATPDase CD39 is involved in the acquisition of the immunoregulatory phenotype by M-CSF-macrophages and ovarian cancer tumor-associated macrophages: Regulatory role of IL-27.

Authors:  Sènan M d'Almeida; Gilles Kauffenstein; Charlotte Roy; Laetitia Basset; Loukas Papargyris; Daniel Henrion; Véronique Catros; Norbert Ifrah; Philippe Descamps; Anne Croue; Pascale Jeannin; Marc Grégoire; Yves Delneste; Julie Tabiasco
Journal:  Oncoimmunology       Date:  2016-04-28       Impact factor: 8.110

Review 10.  Combination cancer immunotherapies tailored to the tumour microenvironment.

Authors:  Mark J Smyth; Shin Foong Ngiow; Antoni Ribas; Michele W L Teng
Journal:  Nat Rev Clin Oncol       Date:  2015-11-24       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.